ielsg32 trial: 88-month follow-up on matrix followed by auto-sct in primary cns lymphoma
Published 3 years ago • 443 plays • Length 7:00Download video MP4
Download video MP3
Similar videos
-
3:59
3-year follow-up from the transform trial: liso-cel is superior to soc in r/r dlbcl
-
1:01
an update on the phase i trial of bms-986393, a novel gprc5d-targeted car-t, in r/r myeloma
-
8:57
outcomes of sct in t-all and t-lbl
-
2:23
prognostic value of alc following bcma car t-cell therapy in multiple myeloma
-
2:19
session highlights: autosct in t-cell lymphoma, classification updates and fertility preservation
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
0:52
highlights from icle 2022
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
46:51
spyros artavanis-tsakonas, “a notch signaling story: it all started at yale“
-
58:44
assessing antigen-specific t-cell functionality with dendritic cell/cd8⁺ t cell co-culture
-
19:31
stat115 chapter 27.2 t cell activation and dysfunction
-
2:08
the venice-1 trial: venetoclax monotherapy in r/r cll
-
1:03
phase i study of asciminib in patients with cp-cml carrying the t315i mutation
-
2:46
transform: liso-cel versus standard of care as second-line therapy for r/r lbcl
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
2:25
current and emerging immune therapies in al amyloidosis: updates on hbi0101 & bispecifics
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:15
results of phase ii study of tislelizumab in r/r nk/t-cell neoplasms
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:37
utilizing the notch1 pathway in the treatment of cll
-
1:24
exciting immunotherapy clinical trials for the management of aml